<DOC>
	<DOCNO>NCT03080961</DOCNO>
	<brief_summary>Genital herpes high prevalence industrialize well develop country . Genital herpes cause genital ulcer , increase risk acquire HIV infection , may transmit mother child birth possible serious consequence . Medical treatment condom partially reduce risk transmission from/ sexual partner . Genital herpes transmission despite use condom think due transfer via skin-to-skin contact unprotected area , HSV-2 transmission may enhance current shave habit genital area lead micro lesion ( laceration ) skin . VIBLOKâ„¢ cream design impede passage virus , HSV-2 , across skin . Bench animal experiment indicate block virus transmission HSV-2 80 % . The objective SAFE trial ass safety performance VIBLOK adult HSV-2 infection compare virus detection extra-genital area application barrier cream .</brief_summary>
	<brief_title>The VIBLOK SAfety perFormancE Trial</brief_title>
	<detailed_description />
	<mesh_term>Herpes Genitalis</mesh_term>
	<criteria>1 . Participant male female least 18 year age 2 . HSV2 seropositive UW Western blot Alegria assay 3 . History recurrent genital herpes least 3 recurrence last year , currently suppressive/ prophylactic therapy , prior start therapy ( antiviral therapy stop least 7 day prior initiation trial product ) . 4 . General good health discretion investigator . 5 . Willing use topical genital therapy aside study device duration trial . 6 . Willing use systemic anti HSV therapy entire study start 7 day prior baseline . 7 . Willing obtain 2 swabs externalgenital area daily duration trial . 8 . Willing keep daily trial diary treatment period . 9 . Negative pregnancy test woman screen . 10 . Willing use contraceptive duration study . 11 . Subject must willing able ( opinion investigator ) understand patient information inform consent form comply clinical trial protocol procedure . 12 . Subject must willing give write informed consent . 1 . Serious medical condition , diabetes , significant autoimmune disease , cancer immunosuppression , etc . discretion investigator likely affect study outcomes 2 . Treatment systemic steroid immunemodulating agent 3 . Participation investigational drug device trial within 30 day prior screen . 4 . Pregnancy breastfeeding , case woman . 5 . Any condition judgment investigator would preclude successful completion clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Barrier cream</keyword>
</DOC>